02 January 2022: Clinical Research
Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France
Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*DOI: 10.12659/MSM.934804
Med Sci Monit 2022; 28:e934804
Table 4 Characteristics of heart failure with reduced ejection fraction (HFrEF) group stratified by the presence of coronary artery disease.
| HFrEF populationN=484 | No CADN=214 | Significant CADN=270 | P-value | |
|---|---|---|---|---|
| Age | 67.50±12.51 | 63.86±13.79 | 70.38±10.57 | |
| Male sex | 375 (77.48%) | 148 (69.16%) | 227 (84.41%) | |
| BMI | 27.89±19.50 | 30.27±28.72 | 26.08±4.69 | 0.036 |
| Atrial fibrillation | 149 (30.78%) | 65 (30.37%) | 84 (31.11%) | 0.861 |
| Chronic kidney disease | 221 (45.66%) | 66 (30.84%) | 155 (57.41%) | |
| Dyslipidemia | 125 (25.82%) | 44 (20.56%) | 81 (30.00%) | 0.080 |
| Diabetes | 142 (29.34%) | 48 (22.43%) | 94 (34.81%) | 0.020 |
| Hypertension | 248 (51.24%) | 86 (40.18%) | 162 (60.00%) | 0.001 |
| Smoking | 133 (27.48%) | 56 (26.17%) | 77 (28.52%) | 0.906 |
| Family history | 78 (16.12%)) | 38 (17.76%) | 40 (14.81%) | 0.164 |
| Valvopathy | 195 (40.29%) | 81 (37.85%) | 114 (42.22%) | 0.317 |
| RVD | 104 (21.49%) | 49 (22.89%) | 55 (20.37%) | 0.244 |
| TAPSE | 16.78±4.50 | 16.15±4.36 | 17.26±4.55 | 0.053 |
| PAPSE | 41.46±13.63 | 41.53±12.75 | 41.41±14.30 | 0.963 |
| Pacemaker | 35 (7.23%) | 15 (7.10%) | 20 (7.41%) | 0.860 |
| Defibrillator | 37 (7.64%) | 12 (5.61%) | 25 (9.26%) | 0.133 |
| NYHA | ||||
| 1 | 23 (4.75%) | 10 (4.67%) | 13 (4.81%) | 1 |
| 2 | 126 (26.03%) | 56 (26.17%) | 70 (25.93%) | |
| 3 | 129 (26.65%) | 56 (26.17%) | 73 (27.04%) | |
| 4 | 43 (8.88%) | 19 (8.89%) | 24 (8.88%) | |
| Systolic blood pressure | 127.37±22.55 | 126.62±22.02 | 127.95±22.99 | 0.566 |
| Diastolic blood pressure | 75.67±14.90 | 77.02±15.53 | 74.62±14.35 | 0.118 |
| Heart rate | 82.76±21.16 | 86.13±20.99 | 80.13±20.97 | 0.005 |
| Troponin | 149.21±58.78 | 87.71±269.36 | 186.97±705.82 | 0.262 |
| NT-ProBNP | 5770.14±8697.02 | 5341.15±8308.36 | 6135.28±9017.84 | 0.365 |
| β-blockers | 283 (58.47%) | 113 (52.80%) | 170 (62.96%) | 0.024 |
| Diuretics | 278 (57.44%) | 116 (54.20%) | 162 (60.00%) | 0.184 |
| Mineralocorticoids | 84 (17.35%) | 36 (16.82%) | 48 (17.77%) | 0.783 |
| ACE/ARA | 238 (49.17%) | 90 (42.05%) | 148 (54.81%) | 0.006 |
| ARNI | 42 (8.67%) | 18 (8.41%) | 24 (8.89%) | 0.853 |
| Ivabradine | 7 (1.45%) | 2 (0.93%) | 5 (1.85%) | 0.471 |
| SAPT | 136 (28.10%) | 33 (15.42%) | 103 (38.15%) | |
| DAPT | 39 (8.06%) | 3 (1.40%) | 36 (13.33%) | |
| DOAC+AVK | 138 (28.51%) | 59 (27.57%) | 79 (29.26%) | 0.683 |
| AAP+OAC | 29 (5.99%) | 4 (1.87%) | 25 (9.26%) | 0.001 |
| β-blockers | 422 (87.19%) | 187 (87.38%) | 235 (87.03%) | 0.748 |
| Diuretics | 377 (77.89%) | 169 (78.97%) | 208 (77.04%) | 0.837 |
| Mineralocorticoids | 212 (43.80%) | 105 (49.06%) | 107 (39.63%) | 0.047 |
| ACE/ARA | 267 (55.16%) | 122 (57.01%) | 145 (53.70%) | 0.545 |
| ARNI | 133 (27.48%) | 68 (31.77%) | 65 (24.07%) | 0.064 |
| Ivabradine | 17 (3.51%) | 7 (3.27%) | 10 (3.70%) | 0.774 |
| SAPT | 87 (17.97%) | 30 (14.02%) | 57 (21.11%) | 0.037 |
| DAPT | 186 (38.43%) | 12 (5.61%) | 174 (64.44%) | |
| DOAC+AVK | 191 (39.46%) | 90 (42.06%) | 101 (37.41%) | 0.299 |
| AAP+OAC | 71 (14.67%) | 3 (1.40%) | 68 (25.18%) |